Restoration of First Phase Insulin Release in Subjects With Type 2 Diabetes Mellitus With Subcutaneous Injection of 20 microg AVE0010 in a Double-Blind, Randomized, Placebo-Controlled, Two-Way Cross Over Intravenous Glucose Challenge Study.
Phase of Trial: Phase I
Latest Information Update: 01 Sep 2014
At a glance
- Drugs Lixisenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Pharmacodynamics
- Acronyms RESTORE
- 22 Feb 2012 Trial phase changed from I/II to I as reported by ClinicalTrials.gov.
- 15 Jun 2010 Actual number of patients added to 22 as reported by ClinicalTrials.gov.
- 12 Aug 2009 Actual end date (Aug 2009) added as reported by ClinicalTrials.gov.